A citation-based method for searching scientific literature

Meng-Lin Li, Xi-Quan Hu, Feng Li, Wen-Jun Gao. Prog Neuropsychopharmacol Biol Psychiatry 2015
Times Cited: 40







List of co-cited articles
361 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
791
40


A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
179
25



Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
267
22

Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
22

Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons.
Min-Juan Wang, Yan-Chun Li, Melissa A Snyder, Huaixing Wang, Feng Li, Wen-Jun Gao. PLoS One 2013
23
34


Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Matthew J Fell, David L McKinzie, James A Monn, Kjell A Svensson. Neuropharmacology 2012
72
17

Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment.
Amr Ellaithy, Jason Younkin, Javier González-Maeso, Diomedes E Logothetis. Trends Neurosci 2015
39
17

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
17


Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex.
Dong Xi, Yan-Chun Li, Melissa A Snyder, Ruby Y Gao, Alicia E Adelman, Wentong Zhang, Jed S Shumsky, Wen-Jun Gao. Neuropsychopharmacology 2011
43
15

CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, David O Calligaro, James A Monn, Darryle D Schoepp, Gerard J Marek. Neuropharmacology 2013
68
15

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Chantal Schlumberger, Daniela Schäfer, Caroline Barberi, Lorenzo Morè, Jens Nagel, Małgorzata Pietraszek, Werner J Schmidt, Wojciech Danysz. Behav Pharmacol 2009
68
15


Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
77
15

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
AnnCatherine M Downing, Bruce J Kinon, Brian A Millen, Lu Zhang, Lin Liu, Margarita A Morozova, Ronald Brenner, Tami Jo Rayle, Laura Nisenbaum, Fangyi Zhao,[...]. BMC Psychiatry 2014
66
15

Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
423
15

Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.
Carolina Muguruza, J Javier Meana, Luis F Callado. Front Pharmacol 2016
30
20

Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
James Maksymetz, Sean P Moran, P Jeffrey Conn. Mol Brain 2017
72
15



Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.
David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gomez. Schizophr Res Treatment 2014
46
12



Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
878
12





Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor.
Hilde Lavreysen, Abdellah Ahnaou, Wilhelmus Drinkenburg, Xavier Langlois, Claire Mackie, Stefan Pype, Robert Lütjens, Emmanuel Le Poul, Andrés A Trabanco, José María Cid Nuñez. Pharmacol Res Perspect 2015
28
17


Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
Subroto Ghose, Kelly A Gleason, Bryan W Potts, Kelly Lewis-Amezcua, Carol A Tamminga. Am J Psychiatry 2009
74
12

Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
568
12

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
John H Krystal, Walid Abi-Saab, Edward Perry, D Cyril D'Souza, Nianjin Liu, Ralitza Gueorguieva, Lisa McDougall, Tracy Hunsberger, Aysenil Belger, Louise Levine,[...]. Psychopharmacology (Berl) 2005
207
12


Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.
Shen Yin, Meredith J Noetzel, Kari A Johnson, Rocio Zamorano, Nidhi Jalan-Sakrikar, Karen J Gregory, P Jeffrey Conn, Colleen M Niswender. J Neurosci 2014
82
12

Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
12

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
12

Rethinking schizophrenia.
Thomas R Insel. Nature 2010
12

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Robert E Litman, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, Stephen R Zukin. Schizophr Res 2016
48
12

Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo.
A Bond, N M Jones, C A Hicks, G M Whiffin, M A Ward, M F O'Neill, A E Kingston, J A Monn, P L Ornstein, D D Schoepp,[...]. J Pharmacol Exp Ther 2000
87
10

Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice.
Vivek Jeevakumar, Christopher Driskill, Alyssa Paine, Millad Sobhanian, Haris Vakil, Brett Morris, Jeremiah Ramos, Sven Kroener. Behav Brain Res 2015
51
10


Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase.
Catherine Trepanier, Gang Lei, Yu-Feng Xie, John F MacDonald. Sci Rep 2013
25
16

Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.
Guy A Higgins, Theresa M Ballard, James N C Kew, J Grayson Richards, John A Kemp, Geo Adam, Thomas Woltering, Shigetada Nakanishi, Vincent Mutel. Neuropharmacology 2004
132
10

Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies.
Hiba Salih, Ion Anghelescu, Iva Kezic, Vikash Sinha, Eef Hoeben, Luc Van Nueten, Heidi De Smedt, Peter De Boer. J Psychopharmacol 2015
35
11

Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor.
José María Cid, Gary Tresadern, Guillaume Duvey, Robert Lütjens, Terry Finn, Jean-Philippe Rocher, Sonia Poli, Juan Antonio Vega, Ana Isabel de Lucas, Encarnación Matesanz,[...]. J Med Chem 2014
37
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.